Published in Women's Health Weekly, September 14th, 2006
According to a study from the United States, "E75 and GP2 are human leukocyte antigen (HLA)-A2-restricted immunogenic peptides derived from the HER2/neu protein. In a E75 peptide-based vaccine trial, pre-existing immunity and epitope spreading to GP2 was detected.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly